Search company, investor...



Other Investors | Alive

About Nanotope

Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n

Headquarters Location

8025 Lamon Avenue, Suite 450

Aurora, Colorado, 60077,

United States

Missing: Nanotope's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nanotope's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nanotope

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nanotope is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Nanotope Patents

Nanotope has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Tissue engineering, Biomaterials, Food additives, Polymers, Molecular biology


Application Date


Grant Date



Related Topics

Tissue engineering, Biomaterials, Food additives, Polymers, Molecular biology



Nanotope Frequently Asked Questions (FAQ)

  • Where is Nanotope's headquarters?

    Nanotope's headquarters is located at 8025 Lamon Avenue, Suite 450, Aurora.

  • What is Nanotope's latest funding round?

    Nanotope's latest funding round is Other Investors.

  • Who are the investors of Nanotope?

    Investors of Nanotope include Fitzsimons Colorado Science and Technology Park.

  • Who are Nanotope's competitors?

    Competitors of Nanotope include OcuNexus Therapeutics, Histogen, Histogenics, Regentis Biomaterials, Juventas Therapeutics, FirstString Research, Synapsin Pharmaceuticals, BioMimetic Therapeutics, VeloMedix, Harvest Technology and 17 more.

Compare Nanotope to Competitors


Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.

FirstString Research

FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.

OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.


CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.nCarticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel.

Nimura Genetic Solutions

Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.

Regentis Biomaterials

Regentis Biomaterials is focused on developing and commercializing hydrogels for tissue regeneration. The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen, combining the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications. The company's flagship product, GelrinC, for the treatment of articular cartilage lesions, is currently in clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.